Skip to main content
SpringerLink
Log in

Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE)

  • Original Article
  • Published:
Japanese Journal of Radiology Aims and scope Submit manuscript

Abstract

Purpose

To identify the risk factors for local recurrence in hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE) with drug-eluting beads (DEB-TACE).

Materials and methods

In this retrospective study, 35 patients (27 males, 8 females; median age 73 years) with 116 tumors (median size 14 mm) treated with DEB-TACE from May 2014 to September 2018 were evaluated. Age, sex, etiology, Child–Pugh class, alpha-fetoprotein, des-gamma-carboxyprothrombin, previous conventional TACE, tumor location, tumor size, tumor number, contact with the liver surface, level of embolization, corona enhancement on CT during hepatic arteriography, vascular lakes, additional embolization with gelatin sponge particles, and supplying vessels on digital subtraction angiography (DSA) after embolization were analyzed.

Results

Univariate analysis showed that advanced age, female, large tumor, contact with the liver surface, and residual supplying vessels were significant risk factors for local recurrence (p = 0.012, 0.0013, 0.0023, 0.025, and < 0.001, respectively). On multivariate logistic analysis, large tumor, contact with the liver surface, and residual supplying vessels on DSA were significant risk factors for local recurrence (p = 0.0026, 0.038, and < 0.001, respectively).

Conclusion

Large tumor size, contact with the liver surface, and residual supplying vessels on DSA were significant risk factors associated with local recurrence after DEB-TACE for HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 1983;148(2):397–401.

    Article  CAS  PubMed  Google Scholar 

  2. Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H, et al. Small hepatocellular carcinoma: treatment with subsegmental transcatheter arterial embolization. Radiology. 1993;188(1):79–83.

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359(9319):1734–9.

    Article  Google Scholar 

  4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

    Article  CAS  Google Scholar 

  5. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35(5):1164–71.

    Article  CAS  PubMed  Google Scholar 

  6. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol. 2008;31(2):269–80.

    Article  PubMed  Google Scholar 

  7. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81.

    Article  CAS  PubMed  Google Scholar 

  8. Sacco R, Bargellini I, Bertini M, Bozzi E, Romano A, Petruzzi P, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22(11):1545–52.

    Article  PubMed  Google Scholar 

  9. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52.

    Article  PubMed  Google Scholar 

  10. Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48(6):571–7.

    Article  CAS  PubMed  Google Scholar 

  12. Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol. 2014;20(22):6995–7004.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jin YJ, Chung YH, Kim JA, Park W, Lee D, Shim JH, et al. Predisposing factors of hepatocellular carcinoma recurrence following complete remission in response to transarterial chemoembolization. Dig Dis Sci. 2013;58(6):1758–65.

    Article  CAS  PubMed  Google Scholar 

  14. Bryant MK, Dorn DP, Zarzour J, Smith JK, Redden DT, Saddekni S, et al. Computed tomography predictors of hepatocellular carcinoma tumour necrosis after chemoembolization. HPB. 2014;16(4):327–35.

    Article  PubMed  Google Scholar 

  15. Vesselle G, Quirier-Leleu C, Velasco S, Charier F, Silvain C, Boucebci S, et al. Predictive factors for complete response of chemoembolization with drug-eluting beads (DEB-TACE) for hepatocellular carcinoma. Eur Radiol. 2016;26(6):1640–8.

    Article  PubMed  Google Scholar 

  16. Ueda K, Matsui O, Kawamori Y, Nakanuma Y, Kadoya M, Yoshikawa J, et al. Hypervascular hepatocellular carcinoma: evaluation of hemodynamics with dynamic CT during hepatic arteriography. Radiology. 1998;206(1):161–6.

    Article  CAS  PubMed  Google Scholar 

  17. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Nakashima Y, Ikeno H, et al. Detection of corona enhancement of hypervascular hepatocellular carcinoma by C-arm dual-phase cone-beam CT during hepatic arteriography. Cardiovasc Intervent Radiol. 2011;34(1):81–6.

    Article  PubMed  Google Scholar 

  18. Maeda N, Osuga K, Mikami K, Higashihara H, Onishi H, Nakaya Y, et al. Angiographic evaluation of hepatic arterial damage after transarterial chemoembolization for hepatocellular carcinoma. Radiat Med. 2008;26(4):206–12.

    Article  PubMed  Google Scholar 

  19. Sueyoshi E, Hayashida T, Sakamoto I, Uetani M. Vascular complications of hepatic artery after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. AJR Am J Roentgenol. 2010;195(1):245–51.

    Article  PubMed  Google Scholar 

  20. Kinugasa H, Nouso K, Takeuchi Y, Yasunaka T, Onishi H, Nakamura S, et al. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012;47(4):421–6.

    Article  PubMed  Google Scholar 

  21. Ekataksin W. The isolated artery: an intrahepatic arterial pathway that can bypass the lobular parenchyma in mammalian livers. Hepatology. 2000;31(2):269–79.

    Article  CAS  PubMed  Google Scholar 

  22. Terayama N, Matsui O, Ueda F, Hattori Y, Nishijima H, Sanada J. CO2 demonstration of multiple extravasations into a subcapsular hematoma of the liver. Cardiovasc Intervent Radiol. 2004;27(3):278–81.

    Article  PubMed  Google Scholar 

  23. Miyayama S, Matsui O. Superselective conventional transarterial chemoembolization for hepatocellular carcinoma: rationale, technique, and outcome. J Vasc Interv Radiol. 2016;27(9):1269–78.

    Article  PubMed  Google Scholar 

  24. Miyayama S, Mitsui T, Zen Y, Sudo Y, Yamashiro M, Okuda M, et al. Histopathological findings after ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma. Hepatol Res. 2009;39(4):374–81.

    Article  PubMed  Google Scholar 

  25. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, et al. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012;35(5):980–5.

    Article  PubMed  Google Scholar 

  26. Grosso M, Vignali C, Quaretti P, Nicolini A, Melchiorre F, Gallarato G, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008;31(6):1141–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, Osaka, 545-8585, Japan

    Mariko M. Nakano, Akira Yamamoto, Masao Hamuro, Shinichi Hamamoto, Atsushi Jogo, Etsuji Sohgawa, Ken Kageyama & Yukio Miki

  2. Department of Diagnostic Radiology, Osaka Saiseikai Nakatsu Hospital, 2-10-39, Shibata, Kita-ku, Osaka, Osaka, 530-0012, Japan

    Norifumi Nishida

  3. Department of Diagnostic and Therapeutic Radiology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa, 920-0293, Japan

    Tetsuya Minami

Authors
  1. Mariko M. Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Akira Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Norifumi Nishida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masao Hamuro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shinichi Hamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Jogo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Etsuji Sohgawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ken Kageyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Tetsuya Minami
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yukio Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Akira Yamamoto.

Ethics declarations

Conflict of interest

On behalf of all authors, the corresponding author states that there is no conflict of interest.

Ethical statement

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

This is a retrospective study. For this type of study, formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakano, M.M., Yamamoto, A., Nishida, N. et al. Risk factors for local recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization with drug-eluting beads (DEB-TACE). Jpn J Radiol 37, 543–548 (2019). https://doi.org/10.1007/s11604-019-00840-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-019-00840-4

Keywords

Search

Navigation